Clinical trials in cardiovascular medicine: Are we looking for statistical significance or clinical relevance?

Heart

Volumn 84, Issue 2, 2000, Pages 129-133

  Willenheimer, R ^a   Dahlof B ^b   Gordon, A ^c  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; FOLLOW UP; HUMAN; METHODOLOGY; OUTCOMES RESEARCH; PATIENT SELECTION; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0033866845     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/heart.84.2.129     Document Type: Short Survey

References (26)

1. The SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
2. Cohn J, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325: 303-10.
3. The SOLVD investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-91.
4. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 1992;327:669-77.
5. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-8.
6. Køber L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin converting enzyme inhibitor trandolapril in patients after myocardial infarction. Trandolapril cardiac evaluation (TRACE) study group. N Engl J Med 1995;333: 1670-6.
7. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55.
8. CIBIS-II Investigators and Committees. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13.
9. The International Steering Committee. Rationale, design, and organization of the metoprolol CR/XL randomized intervention trial in heart failure (MERIT-HF). Am J Cardiol 1997;80 (9B):54J-58J.
10. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 1999;353:2001-7.
11. Pitt B. ACE inhibitor co-therapy in patients with heart failure: rationale for the randomized aldactone evaluation study (RALES). Eur Heart J 1995;16 (Suppl N):107-10.
12. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17.
13. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-33.
14. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The cardiac arrhythmia suppression trial. N Engl J Med 1991;324:781-8.
15. The Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992;327:227-33.
16. Waldo AL, Camm AJ, deRuyter H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival with oral d-sotalol. Lancet 1996;348:7-12.
17. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. Dofetilide in patients with left ventricular dysfunction and either heart failure or acute myocardial infarction: rationale, design, and patient characteristics of the DIAMOND studies. Clin Cardiol 1997;20:704-10.
18. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish investigations of arrhythmia and mortality on dofetilide study group. N Engl J Med 1999;341:857-65.
19. Pedersen TR. Six-year follow-up of the Norwegian multicenter study on timolol after acute myocardial infarction. N Engl J Med 1985;313:1055-8.
20. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995;345: 669-85.
21. Woods KL, Fletcher S. Long-term outcome after intravenous magnesium sulphate in suspected acute myocardial infarction: the second Leicester intravenous magnesium intervention trial (LIMIT-2). Lancet 1994;343:816-9.
22. Seelig MS, Elin RJ, Antman EM. Magnesium in acute myocardial infarction: still an open question. Can J Cardiol 1998;14:745-9.
23. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the cooperative north Scandinavian enalapril survival study (CONSENSUS). N Engl J Med 1987;316:1429-35.
24. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS study group. Circulation 1999;100:2312-8.
25. Houghton AR, Cowley AJ. Why are angiotensin converting enzyme inhibitors underutilised in the treatment of heart failure by general practitioners? Int J Cardiol 1997;59:7-10.
26. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N Engl J Med 2000;342: 145-53.